论文部分内容阅读
目的:观察益肝方合阿德福韦酯对慢性乙肝肝纤维化的临床疗效。方法:将113例患者按随机数字表法分为治疗组58例和对照组55例,治疗组给予益肝方及阿德福韦酯胶囊口服,连服12个月,对照组给予阿德福韦酯胶囊口服,疗程同治疗组。分别于6个月、12个月治疗结束后,检测患者血清HBV-DNA转阴率、肝功能(ALT、AST)、血清肝纤维化指标(HA、IV-C、PCIII、LN)、血清TGF-β1、TIMP-1、TNF-α、PDGF等因子浓度及患者门静脉、脾静脉宽度及脾脏厚度,均与治疗前及对照组对比,同时观察药物不良反应。结果:治疗组中HBV-DNA转阴率明显提高,各项指标明显下降,与治疗前及对照组相比具有显著差异性(P<0.05)。结论:益肝方合阿德福韦酯治疗肝纤维化可以明显提高临床疗效。
Objective: To observe the clinical effect of Yifang Recipe adefovir dipivoxil on chronic hepatitis B liver fibrosis. Methods: According to the random number table, 113 patients were divided into treatment group (58 cases) and control group (55 cases). The treatment group was treated with Yifangfang and adefovir dipivoxil capsules for 12 months. The control group was given adefovir Wei ester capsules oral treatment with the treatment group. Serum HBV-DNA negative rate, liver function (ALT, AST), serum hepatic fibrosis index (HA, IV-C, PCIII, LN) and serum TGFβ were measured at the end of 6 months and 12 months respectively. β1, TIMP-1, TNF-α, PDGF and other factors in patients with portal vein, splenic vein width and spleen thickness were compared with before treatment and control group, and observed adverse drug reactions. Results: The HBV-DNA negative rate in the treatment group was significantly higher than that in the control group (P <0.05). Conclusion: Yifang Fang adefovir dipivoxil treatment of liver fibrosis can significantly improve the clinical efficacy.